Topic: Hiv Prep

6 chapters across the catalog

Leave it to Bibi
Episode 1774 1:35:03 - 1:39:21

1774: Leave it to Bibi

Lenacapavir Approval, Breakthrough HIV Prevention Injection

The FDA has approved Lenacapavir, a twice-yearly injection that is reportedly over 99.9% effective at preventing HIV. Manufacturer Gilead Sciences set the list price at approximately $28,000 per year. While medical professionals hail it as a breakthrough for those who struggle with daily pill compliance, critics question the high cost and the reliance on federal funding for access.

Inrush
Episode 1513 1:23:16 - 1:27:54

1513: Inrush

Dovato HIV Medication Commercial Analysis

An analysis of a television commercial for the HIV medication Dovato focuses on the claim that patients who remain "undetectable" can no longer transmit the virus through sex. The discussion examines the specific phrasing used in pharmaceutical warnings regarding side effects such as lactic acid buildup and liver problems.

Bald Nancy
Episode 1371 1:23:07 - 1:28:25

1371: Bald Nancy

Spirit Airlines Meltdown, Pfizer-Mectin, HIV PrEP Comparison

Spirit Airlines experienced a massive operational meltdown due to staffing shortages and scheduling system failures. In medical news, Dr. Anthony Fauci discussed a new orally administered drug for early COVID-19 treatment, which the hosts dub "Pfizer-Mectin." Fauci compared the potential treatment to HIV PrEP, leading to speculation about whether the government is pivoting toward a daily pill regimen for virus management.

Juloon
Episode 754 1:50:12 - 1:54:11

754: Juloon

Truvada PrEP Studies and Media Misinformation

A Washington Post article claiming 100% effectiveness for the HIV prevention pill Truvada is scrutinized. The hosts point out a correction in the article regarding a different study that showed only 86% effectiveness. They argue that misleading headlines about "pre-exposure prophylaxis" (PrEP) could lead to dangerous behavior and increased infection rates.

Walking Bear
Episode 642 1:58:32 - 2:02:30

642: Walking Bear

Truvada Marketing and the "Truvada Whore" Label

An investigation into the aggressive marketing of the drug Truvada (PrEP) for HIV prevention, particularly within the porn industry and on apps like Grindr. The segment criticizes NPR and Kaiser Permanente for "native advertising" that downplays the continued need for condoms, noting the emergence of the controversial term "Truvada Whore."

Huma-Gate
Episode 427 2:32:07 - 2:37:07

427: Huma-Gate

Truvada FDA Approval, HIV PrEP and AIDS Industry

The FDA approved Truvada for use as Pre-Exposure Prophylaxis (PrEP) to prevent HIV infection in high-risk individuals. The hosts criticize the $14,000 to $16,000 annual cost of the drug and suggest the "AIDS industry" is a scam. They reference the documentary House of Numbers and the claims of the scientist who originally discovered the HIV virus.